MX2012012063A - Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd). - Google Patents

Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd).

Info

Publication number
MX2012012063A
MX2012012063A MX2012012063A MX2012012063A MX2012012063A MX 2012012063 A MX2012012063 A MX 2012012063A MX 2012012063 A MX2012012063 A MX 2012012063A MX 2012012063 A MX2012012063 A MX 2012012063A MX 2012012063 A MX2012012063 A MX 2012012063A
Authority
MX
Mexico
Prior art keywords
antibody
copd
exacerbation
patient
binding
Prior art date
Application number
MX2012012063A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Coyle
Donna Finch
Martin Stampfli
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2012012063A publication Critical patent/MX2012012063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012012063A 2010-04-16 2011-04-18 Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd). MX2012012063A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32524110P 2010-04-16 2010-04-16
US41610210P 2010-11-22 2010-11-22
PCT/US2011/032910 WO2011130745A1 (en) 2010-04-16 2011-04-18 Compositions and methods for treating copd exacerbation

Publications (1)

Publication Number Publication Date
MX2012012063A true MX2012012063A (es) 2013-03-21

Family

ID=44799068

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012063A MX2012012063A (es) 2010-04-16 2011-04-18 Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd).

Country Status (11)

Country Link
US (1) US20130149312A1 (enExample)
EP (1) EP2558112A4 (enExample)
JP (1) JP2013525310A (enExample)
KR (1) KR20130086141A (enExample)
CN (1) CN102985100A (enExample)
AU (1) AU2011239402A1 (enExample)
BR (1) BR112012026545A2 (enExample)
CA (1) CA2796083A1 (enExample)
MX (1) MX2012012063A (enExample)
RU (1) RU2012148721A (enExample)
WO (1) WO2011130745A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
JPWO2015182121A1 (ja) * 2014-05-29 2017-04-27 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療
WO2016168696A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Methods to improve induction of iga antibodies by vaccines
WO2016197087A1 (en) 2015-06-05 2016-12-08 The University Of Rochester Shape-memory polymers and methods of making and use thereof
KR102208549B1 (ko) * 2019-05-16 2021-01-27 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물
JP2023529764A (ja) * 2019-12-02 2023-07-12 アルタバント・サイエンシズ・ゲーエムベーハー 下気道障害の処置
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026003765A1 (en) * 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Also Published As

Publication number Publication date
RU2012148721A (ru) 2014-05-27
CA2796083A1 (en) 2011-10-20
BR112012026545A2 (pt) 2019-09-24
AU2011239402A1 (en) 2012-10-25
EP2558112A4 (en) 2014-06-18
US20130149312A1 (en) 2013-06-13
WO2011130745A1 (en) 2011-10-20
KR20130086141A (ko) 2013-07-31
EP2558112A1 (en) 2013-02-20
CN102985100A (zh) 2013-03-20
JP2013525310A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
US20240199751A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2018253118B2 (en) Treatment of asthma with anti-TSLP antibody
RU2734490C2 (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
JP5137053B2 (ja) 抗ｂ因子抗体もしくはその抗原結合性フラグメント、それを含む組成物、抗原結合性ポリペプチド、および治療薬
US20130149312A1 (en) Compositions and methods for treating copd exacerbation
JP6458086B2 (ja) 変形性関節症の治療
JP2024530541A (ja) 粘膜の癒着を予防、緩和或いは治療する薬物及びその応用
EP3957364A1 (en) A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
CN101022828B (zh) B因子、补体旁路的抑制及与此相关的方法
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
HK40076109B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40076109A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
NZ727717B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EP2747785A1 (en) Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition
BR122019023269B1 (pt) composição farmacêutica compreendendo um anticorpo que se liga especificamente ao receptor da interleucina-4 (il-4r) para uso no tratamento de asma moderada a grave ou grave em um indivíduo
HK1211605B (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
FA Abandonment or withdrawal